IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+37.65%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$241M
AUM Growth
+$241M
(+20%)
Cap. Flow
-$3.2M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
54.79%
Holding
92
New
13
Increased
8
Reduced
23
Closed
11
Top Buys
| 1 |
Vaxcyte
PCVX
|
$12M |
| 2 |
Biohaven
BHVN
|
$11.6M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$6.35M |
| 4 |
BioXcel Therapeutics
BTAI
|
$5.37M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$4.9M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$12.9M |
| 2 |
Ardelyx
ARDX
|
$5.13M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$5.03M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$3.43M |
| 5 |
Altimmune
ALT
|
$3.27M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RVNC
76
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-100,000
| Closed | -$2.7M |
|
77
scPharmaceuticals
SCPH
$296M
| – | – |
-479,383
| Closed | -$3.13M |
|
78
Prothena Corp
PRTA
$452M
| – | – |
0
| – | – |
|
79
Seres Therapeutics
MCRB
$162M
| – | – |
-6,566
| Closed | -$843K |
|
80
Krystal Biotech
KRYS
$4.35B
| – | – |
0
| – | – |
|
|
IVA
81
Inventiva
IVA
$802M
| – | – |
-13,236
| Closed | -$48K |
|
82
Insmed
INSM
$30.3B
| – | – |
0
| – | – |
|
83
Geron
GERN
$893M
| – | – |
0
| – | – |
|
84
Clene
CLNN
$55.8M
| – | – |
0
| – | – |
|
85
Axsome Therapeutics
AXSM
$6.09B
| – | – |
0
| – | – |
|
86
Arvinas
ARVN
$580M
| – | – |
0
| – | – |
|
87
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
0
| – | – |
|
88
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-2,800
| Closed | -$560K |
|
89
Akero Therapeutics
AKRO
$3.65B
| – | – |
0
| – | – |
|
90
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
91
Stoke Therapeutics
STOK
$1.08B
| – | – |
0
| – | – |
|
92
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|